Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 in second-line advanced esophageal squamous cell carcinoma
CTR20190427Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- May 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Alphamab Oncology. Started May 2019; status: completed.
02
Drugs
erfonrilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20190427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190427.